Metamark Announces Agreement with Blue Cross and Blue Shield of Texas

7/12/2016 | Press Release

Metamark Announces Agreement with Blue Cross and Blue Shield of Texas

Company continues to expand access to array of innovative urology diagnostics

July 12, 2016 9:00 AM Eastern Daylight Time

Cambridge, Mass. — (PRNewswire) — Metamark Genetics, Inc., (“Metamark” or the “Company”), a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective June 1, 2016, the Company signed an agreement with Blue Cross and Blue Shield of Texas (BCBSTX) to provide its members with in-network access to Metamark’s offering of urology specialized diagnostics.

“Metamark is delighted to be recognized as an in-network provider with Blue Cross and Blue Shield of Texas. Our continued momentum with payers across the US reflects the substantial value our comprehensive suite of products and services provides to patients, physicians, and insurers” said Jerry Williamson, president and chief executive officer. “We maintain our strong commitment to improve the care of patients with urologic cancer by expanding access to vital, decision-making information throughout the complete diagnostic and therapeutic care journey.”

Metamark has previously announced in-network agreements with additional large Blue Cross and Blue Shield Plans and also has agreements in place with the largest PPO networks in the country.

About Metamark® 
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company’s proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, and kidney cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.

For more information, please visit the company’s website: www.metamarkgenetics.com.

Metamark® is a registered trademark of Metamark Genetics, Inc. 


Contact:
Metamark Genetics, Inc. 
Jerry Williamson, 617-583-1450 
President & Chief Executive Officer

###